Impacto de la mutación T315I en el pronóstico de la leucemia mieloide crónica
Bushra Kaleem, Sadaf Shahab, Tahir Sultan Shamsi · 2024
Read Impacto de la mutación T315I en el pronóstico de la leucemia mieloide crónica by Bushra Kaleem, Sadaf Shahab, Tahir Sultan Shamsi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11661547.txt.
Description
Bushra Kaleem, Sadaf Shahab, and Tahir Sultan Shamsi published a study in 2024, written in Spanish, on a mutation that blunts the main drugs for chronic myeloid leukemia. The mutation, called T315I, changes the target protein so standard inhibitors fail to bind. The team asked how often it appears in patients already failing treatment and what it means for their future.
Among 102 patients responding poorly to therapy, about one in five carried the mutation, detected by a targeted test and confirmed by sequencing. Carriers were followed for up to ninety-six months. Nearly sixty percent of carriers progressed to the dangerous blast phase, and progressors were more likely to carry the mutation. Overall survival among carriers was about eighty-two percent across the study period.
Catalog record
| CREATOR | Bushra Kaleem, Sadaf Shahab, Tahir Sultan Shamsi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |